MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2009-12-30
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT01040871
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent - UZ GENT, Hematologie, 9K12IE 9de verdiep- polikliniek Hematologie, Gent, Belgium
Dose Escalation Study of MLN4924 in Adults With Melanoma
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT01011530
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Santa Monica, California, United States
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00963820
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸James R. Berenson, MD, Inc, West Hollywood, California, United States
🇺🇸Weill-Cornell Medical College, New York, New York, United States
Study of MLN8237 in Participants With Advanced Solid Tumors
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00962091
- Locations
- 🇺🇸
Premiere Oncology, A Medical Corporation, Santa Monica, California, United States
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
- Conditions
- Advanced Non-hematologic MalignanciesAdvanced Metastatic Melanoma
- Interventions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT00948467
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Wayne State University Karmanos Cancer Institute, Detriot, Michigan, United States
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00935844
- Locations
- 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Fox Chase Cancer Center, Rockledge, Pennsylvania, United States
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00932698
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
- Conditions
- Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
- Interventions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 206
- Registration Number
- NCT00931918
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸Georgia Cancer Specialists, Atlanta, Georgia, United States
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
- Conditions
- Myelodysplastic SyndromeAcute Myelogenous LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00911066
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme
- Interventions
- Drug: Tandutinib, bevacizumab, and temozolomide
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2009-05-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00904852